4.6 Article

Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors

Journal

NEURO-ONCOLOGY
Volume 24, Issue 6, Pages 1020-1028

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/noab276

Keywords

ADC; ICI; IDH wild type; MRI; recurrent glioblastoma

Funding

  1. American Cancer Society (ACS) Research Scholar Grant [RSG-15-003-01-CCE]
  2. University of California Research Coordinating Committee (BME)
  3. UCLA Jonsson Comprehensive Cancer Center Seed Grant
  4. UCLA SPORE in Brain Cancer [NIH/NCI 1P50CA211015-01A1]
  5. NIH/NCI [1R21CA223757-01]
  6. NIH-NIGMS Training Grant [GM008042]

Ask authors/readers for more resources

Elevated post-treatment ADC values may serve as an early imaging biomarker for predicting overall survival in patients with recurrent IDH wild-type GBM receiving immune checkpoint inhibitor treatment. This finding could potentially guide treatment decisions and prognosis assessment in these patients.
Background Diffusion MRI estimates of the apparent diffusion coefficient (ADC) have been shown to be useful in predicting treatment response in patients with glioblastoma (GBM), with ADC elevations indicating tumor cell death. We aimed to investigate whether the ADC values measured before and after treatment with immune checkpoint inhibitors (ICIs) and the changes in these ADC values could predict overall survival (OS) in patients with recurrent IDH wild-type GBM. Methods Forty-four patients who met the following inclusion criteria were included in this retrospective study: (i) diagnosed with recurrent IDH wild-type GBM and treated with either pembrolizumab or nivolumab and (ii) availability of diffusion data on pre- and post-ICI MRI. Tumor volume and the median relative ADC (rADC) with respect to the normal-appearing white matter within the enhancing tumor were calculated. Results Median OS among all patients was 8.1 months (range, 1.0-22.5 months). Log-rank test revealed that higher post-treatment rADC was associated with a significantly longer OS (median, 10.3 months for rADC >= 1.63 versus 6.1 months for rADC < 1.63; P = .02), whereas tumor volume, pretreatment rADC, and changes in rADC after treatment were not significantly associated with OS. Cox regression analysis revealed that post-treatment rADC significantly influenced OS (P = .02, univariate analysis), even after controlling for age and sex (P =.01, multivariate analysis), and additionally controlling for surgery after ICI treatment (P = .045, multivariate analysis). Conclusions Elevated post-treatment rADC may be an early imaging biomarker for OS benefits in GBM patients receiving ICI treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available